White Paper

Cell & Gene Therapy Executive Survey: Entering The Execution Era

scientists working in laboratory-GettyImages-525440711

A new survey of cell and gene therapy executives finds that the industry’s defining question has shifted from “will it work?” to “will it sell?” Leaders remain confident in the biology, but the risk has moved downstream into regulation, funding, payment, and delivery. Regulatory optimism is returning. Yet companies closest to market report the least confidence that FDA reviews are applied consistently, and what they want most is predictability, not just speed. Investors now expect proof that a therapy can be financed, reimbursed, and delivered. At the same time, payers question how long benefits last and health systems struggle to treat patients at scale. The report outlines four connected priorities: regulatory execution, investable business models, scalable access and delivery, and competitive speed. It also explores why approaches like in vivo CAR-T are gaining attention as global competition grows. Use these insights to strengthen your development plan and build the regulatory, evidence, and delivery strategy that turns clinical success into lasting patient access.

Access The White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene